INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 222 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is 1.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $234,000 | -34.3% | 16,800 | -23.1% | 0.00% | 0.0% |
| Q4 2021 | $356,000 | -46.3% | 21,855 | -51.0% | 0.00% | -50.0% |
| Q3 2021 | $663,000 | -44.8% | 44,623 | -25.8% | 0.00% | -60.0% |
| Q2 2021 | $1,200,000 | +81.3% | 60,100 | +109.4% | 0.01% | +66.7% |
| Q1 2021 | $662,000 | +138.1% | 28,704 | +155.3% | 0.00% | +200.0% |
| Q4 2020 | $278,000 | -77.8% | 11,244 | -43.5% | 0.00% | -88.9% |
| Q1 2020 | $1,252,000 | +78.9% | 19,898 | +252.9% | 0.01% | +80.0% |
| Q4 2019 | $700,000 | -10.6% | 5,639 | -52.2% | 0.01% | -28.6% |
| Q3 2019 | $783,000 | +66.6% | 11,800 | +180.8% | 0.01% | +133.3% |
| Q1 2019 | $470,000 | -2.1% | 4,202 | +10.6% | 0.00% | 0.0% |
| Q3 2018 | $480,000 | – | 3,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
| Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
| DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
| GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
| BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
| Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
| ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
| Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
| QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
| Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |